FTC antitrust war wages on
01 March 2009
Managing Intellectual Property
The US Federal Trade Commission's campaign against reverse payments between innovator pharmaceutical companies and generics stepped up a gear last month
Eileen McDermott, New York
In its latest bid to curb these payments , the FTC filed a complaint against Solvay Pharmaceuticals and three generic drug makers.
The complaint alleges that Watson Pharmaceuticals, Par Pharmaceuticals and Paddock Laboratories agreed to abandon their Abbreviated New Drug Application (ANDA) with the Food and Drug Administration challenging Solvay's patent on AndroGel and to delay generic entry into the market until 2015 in exchange for "substantial compensation", including $10 million a year for six years to Par and $6 million up front to Paddock.
According to the FTC, this practice constitutes anticompetitive behaviour not anticipated by the Hatch-Waxman Act. "Solvay has unlawfully extended its monopoly not on the strength of its patent, but rather by compensating its potential competitors," said the complaint.
In a statement, commissioner Jon Leibowitz of the FTC said: "This is yet another example of pharmaceutical companies turning competition on its head. ....
Only subscribers have complete access to Managing IP Magazine,
log in or
subscribe now.
Alternatively take a
free trial, giving you 48-hour access to Managing IP Magazine (some articles and surveys may be excluded).
Subscribe Now
This article is available to subscribers. Please click subscribe to read the rest of the article.
Subscribe
Take a free trial
Please take a free 48-hour trial to gain limited access. Some articles and surveys may be excluded.
Take a free trial